TRIPOD Checklist: Prediction Model Development

Section	Item	Checklist description	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract				
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page 1/ Line3- 4	Title
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Page 2/ Line35-67	Abstract/Para 1-4
Introduction				
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page 3/ Line 73-98	Introductio/Para1-2
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page 3-4 / Line 99-108	Introductio/Para 3
Methods				
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, ifapplicable.	Page 4/Line112-123	Methods/Para 1
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	N/A (All datas were from the TCGA)	N/A (All datas were from the TCGA)
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	N/A (All datas were downloaded from the TCGA)	N/A (All datas were downloaded from the TCGA)
	5b	Describe eligibility criteria for participants.	N/A (All datas were from the TCGA)	N/A (All datas were from the TCGA)
	5c	Give details of treatments received, if relevant.	N/A (All datas were from the TCGA)	N/A (All datas were from the TCGA)
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page 4-5/Line 125-167	Methods/Para 2-5
	6b	Report any actions to blind assessment of the outcome to be predicted.	N/A (All datas were from the TCGA)	N/A (All datas were from the TCGA)
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Page 4-5/Line 134-167	Methods/Para 3-5
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	N/A (All datas were from the TCGA)	N/A (All datas were from the TCGA)
Sample size	8	Explain how the study size was arrived at.	Page 4/Line112-123	Methods/Para 1

Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Page 4/Line112-123	Methods/Para 1
Statistical analysis methods	10a	Describe how predictors were handled in the analyses.	Page 7/Line 213-219	Methods/Para 10
	10b	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Page 7/Line 213-219	Methods/Para 10
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page 7/Line 213-219	Methods/Para 10
Risk groups	11	Provide details on how risk groups were created, if done.	Page 5/Line 136-144	Methods/Para 3
Results				
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Page 7/Line 224-228	Rrsults/Para 1
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Page 7/Line 233-234, Page 81/Line 260-261	Rrsults/Para 2
Model development	14a	Specify the number of participants and outcome events in each analysis.	Page 7-9/Line 233-273,	Rrsults/Para 2 and Table 1
	14b	If done, report the unadjusted association between each candidate predictor and outcome.	Page 9/Line 277-290	Rrsults/Para 3
Model specification	15a	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Page 8/Line 248-253,	Rrsults/Para 2
	15b	Explain how to the use the prediction model.	Page 8-9 /Line 253-273	Rrsults/Para 2
Model performance	16	Report performance measures (with CIs) for the prediction model.	Page 9/Line 277-290	Rrsults/Para 3
Discussion				
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Page 13/Line 466-470	Discussion/Para 8
Interpretation	19b	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Page 11/Line 394-406,	Discussion/Para 2
Implications	20	Discuss the potential clinical use of the model and implications for future research.	Page 13-14/Line 473-484	Conclsions
Other information				
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	N/A(There is no availability of supplementary resources)	N/A
Funding	22	Give the source of funding and the role of the funders for the present study.	Page 14/Line 487-490	Acknowledgments

Article Information: https://dx.doi.org/10.21037/gs-22-267
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.